Bone Biologics Corporation

NasdaqCM:BBLG Stock Report

Mkt Cap: US$2.0m

Bone Biologics Balance Sheet Health

Financial Health criteria checks 6/6

Bone Biologics has a total shareholder equity of $3.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.0M and $1.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$4.45m
EquityUS$3.79m
Total liabilitiesUS$1.18m
Total assetsUS$4.98m

Recent financial health updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07
Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18
We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Recent updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07
Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Bone Biologics prices $5.1M underwritten public offering

Oct 07

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18
We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Financial Position Analysis

Short Term Liabilities: BBLG's short term assets ($5.0M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: BBLG has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: BBLG is debt free.

Reducing Debt: BBLG currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BBLG has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: BBLG is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth